Thomas McNaughton

This profile gathers the share dealings of Thomas McNaughton across 2 companies, led by Harvard Apparatus Regenerative Technology, Inc. and Harvard Bioscience Inc. Over a trading history stretching from 4 June 2010 to 15 June 2018, the count stands at 24 filings.

The open-market record is one-sided, with 15 purchases worth €200k and not one sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 5 share grants and 1 option exercise. In 2018 alone, the filings show 1 purchase and no sales.

In size, the median ticket on the buying side is €9,510. 3 out of 3 purchases came within 30 days of a purchase by at least one other insider of the same company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. For 15 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 20% of cases, with a median move of -24.4%. This is a record of the past, not a forecast.

Most recently, on 19 June 2018, the filings show an open-market purchase worth €9,510 in Harvard Apparatus Regenerative Technology, Inc. The median gap between a trade and its publication by SEC (Form 4) is 3 days. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.